Sosyal kuruluşlar için hibeler ve destekler

Bases reguladoras Galicia Exporta Organismos Intermedios 2026, cofinanciadas FEDER, concurrencia no competitiva, mínimis general

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Otras Prestaciones económicas

Dönem: 28/1/2026 – —

Bases reguladoras Galicia Exporta Organismos Intermedios 2026, cofinanciada FEDER, concurrencia no competitiva, mínimis pesca

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Otras Prestaciones económicas

Dönem: 15/1/2026 – —

Bases reguladoras Galicia Exporta Organismos Intermedios 2026, cofinanciadas FEDER, concurrencia no competitiva, mínimis agrícola

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Otras Prestaciones económicas

Dönem: 15/1/2026 – —

Bases reguladoras Ticket Innova 2026, concurrencia no competitiva, mínimis general

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Investigación, desarrollo e innovación

Dönem: 26/1/2026 – —

Bases reguladoras Ticket Innova 2026, concurrencia no competitiva, mínimis pesca

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Investigación, desarrollo e innovación

Dönem: 21/1/2026 – —

Bases reguladoras TICKET INNOVA 2026, concurrencia no competitiva, mínimis agrícola

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Investigación, desarrollo e innovación

Dönem: 21/1/2026 – —

Bases reguladoras financiación Igape-pymes 2026, concurrencia no competitiva, mínimis general

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Industria y Energía

Dönem: 26/1/2026 – —

Bases reguladoras Financiación Igape-pymes 2026, concurrencia no competitiva, mínimis pesca

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Industria y Energía

Dönem: 21/1/2026 – —

Bases reguladoras Financiación Igape-pymes 2026, concurrencia no competitiva, mínimis agrícola

AUTONOMICA - GALICIA - INSTITUTO GALLEGO DE PROMOCIÓN ECONÓMICA (IGAPE) ·

Industria y Energía

Dönem: 21/1/2026 – —

Soutenir les projets de plantation d'arbres

Fransa · Bourgogne-Franche-Comté

Kimler başvurabilir Commune · Intercommunalité / Pays

Le Chèque-arbre 71 est un dispositif spécifique au Département de Saône-et-Loire destiné aux collectivités et aux associations dont l'objet social est en lien avec l'environnement et la préservation des patrimoines, pour soutenir des projets de plantations à partir d'un minimum de 15 arbres, avec panachage, selon une liste d'essences définie. Le financement possible varie de 500 € à 2000 €, en fonction du montant de dépenses éligibles retenues et du nombre d'arbres plantés.

Dönem: 5/1/2026 – —

Kırsal Merkezi Olmayan Su Sistemi Hibe Programı

Amerika Birleşik Devletleri · US

Kimler başvurabilir Others (see text field entitled "Additional Information on Eligibility" for clarification)

DWS Hibe Programı, düşük ila orta gelirli bireylerin sahip oldukları veya sahip olacakları hane halkı su kuyularının ve bireysel olarak sahip olunan merkezi olmayan atık su sistemlerinin belirli maliyetlerini finanse etmelerine yardımcı olmak amacıyla kurulmuştur. Uygun kar amacı gütmeyen kuruluşlara, bireysel olarak sahip olunan su kuyusu sistemleri ve/veya bireysel olarak sahip olunan atık su sistemleri için uygun bireylere kredi ve alt hibe sağlamak üzere döner bir fon oluşturmak ve sürdürmek için hibeler verilir. Kredi ve/veya alt hibe fonları, birey tarafından merkezi olmayan su kuyusu veya atık su sistemlerini inşa etmek, yenilemek, rehabilite etmek veya değiştirmek için kullanılabilir. Su kuyusu sistemleri için fonlar, bir kuyudan pompalanan suyun bir ev su dağıtım sistemine girdiği nokta olan eve giriş noktasına kadar kullanılabilir. Atık su sistemleri için, giriş noktası yerine çıkış noktası ikame edilir. Çıkış noktası, atık suyun ev atık su toplama sisteminden septik tanka ve drenaj alanına çıktığı noktadır. DWS hibe fonları, kar amacı gütmeyen alıcı tarafından DWS kredileri ve/veya alt hibeleri sağlamakla ilişkili idari giderleri ödemek için kullanılabilir.

NEA/AC Regional Annual Program Statement

Amerika Birleşik Devletleri · US

Kimler başvurabilir Others (see text field entitled "Additional Information on Eligibility" for clarification)

The Bureau of Near Eastern Affairs’ Office of Assistance Coordination (NEA/AC) of the U.S. Department of State announces an open competition for organizations to submit a statement of interest (SOI) for innovative foreign assistance programs benefitting partner countries that also advance U.S. commercial diplomacy and place American interests first. SOI must demonstrate how projects will leverage foreign assistance for U.S. partners as a tool of statecraft to advance U.S. economic, security, and diplomatic objectives. Programming should promote trade, not aid, by leveraging assistance resources to champion American enterprise and infrastructure and catalyze private capital through market principles.

Middle East Regional Cooperation (MERC)

Amerika Birleşik Devletleri · US

Kimler başvurabilir Others (see text field entitled "Additional Information on Eligibility" for clarification)

The Middle East Regional Cooperation (MERC) Program supports joint scientific research and innovation partnerships between the United States, Israel, and countries across the Middle East and North Africa (MENA). The program funds applied research projects that address shared regional challenges while advancing U.S. economic, technological, and strategic interests. MERC is designed to bring together researchers, technical experts, and institutions to work on projects that go beyond basic research and demonstrate clear potential for application, commercialization, and broader adoption. MERC prioritizes efforts that strengthen U.S. technological leadership, expand opportunities for U.S. businesses, promote the use of U.S. technologies, and build long-term partnerships in the region. The program places strong emphasis on collaboration. All projects must include organizations from Israel and at least one eligible MENA country or territory. MERC welcomes U.S. participation, particularly when it adds technical expertise, supports market expansion for U.S. companies, or helps connect research to markets. Projects should demonstrate a clear plan for using and scaling results and how the outcomes benefit priorities of the United States and the participating countries. Overall, MERC aims to strengthen regional cooperation by supporting high-quality scientific partnerships that produce tangible results. By connecting U.S., Israeli, and MENA organizations, the program helps build networks, promote innovation, and create opportunities for economic growth, peaceful and mutually beneficial collaboration, and long-term stability in the region.

NEA/AC Regional Annual Program Statement

Amerika Birleşik Devletleri · US

Kimler başvurabilir Others (see text field entitled "Additional Information on Eligibility" for clarification)

The Bureau of Near Eastern Affairs’ Office of Assistance Coordination (NEA/AC) of the U.S. Department of State announces an open competition for organizations to submit a statement of interest (SOI) for innovative foreign assistance programs benefitting partner countries that also advance U.S. commercial diplomacy and place American interests first. SOI must demonstrate how projects will leverage foreign assistance for U.S. partners as a tool of statecraft to advance U.S. economic, security, and diplomatic objectives. Programming should promote trade, not aid, by leveraging assistance resources to champion American enterprise and infrastructure and catalyze private capital through market principles. SOI are to be submitted via MyGrants.

DoW Rare Cancers Concept Award

Amerika Birleşik Devletleri · US

Kimler başvurabilir Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers. Distinctive Features: Preliminary data are not required. Due to the blinded nature of the review process, identifying or making references to the Principal Investigator (PI), collaborator(s), or their organization(s) in the proposal Project Narrative, Supporting Documentations, Impact Statement, Justification Statement, and Statement of Work (SOW) is prohibited and will result in administrative rejection of the application.

Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)

Amerika Birleşik Devletleri · US

Kimler başvurabilir City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · State governments · Public housing authorities/Indian housing authorities · Special district governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · Private institutions of higher education · Small businesses · Native American tribal governments (Federally recognized) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · For profit organizations other than small businesses · Public and State controlled institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

This Notice of Funding Opportunity (NOFO) invites a single cooperative agreement application for the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D). The purpose of CaRe-T1D is to support innovative, discovery and mechanistic research through the study of human cardiovascular (CV) tissue. This research seeks to better understand cardiovascular disease (CVD) in type 1 diabetes, highlight differences compared to type 2 diabetes, and ultimately guide the development of therapies to treat this major cause of morbidity and mortality for individuals with type 1 diabetes. To achieve these goals, the Resource Center will expand the CaRe-T1D biorepository of human CV tissue, further develop the data commons for data sharing and for artificial intelligence (AI) tools, coordinate the research activities of the investigative teams in the CaRe-T1D consortium, and make CaRe-T1D resources accessible to the broader research community. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)

Amerika Birleşik Devletleri · US

Kimler başvurabilir Private institutions of higher education · Small businesses · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Public and State controlled institutions of higher education · City or township governments · For profit organizations other than small businesses · Public housing authorities/Indian housing authorities · State governments · County governments · Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification)

The purpose of this notice of funding opportunity (NOFO) is to establish a Center that trains researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics and to advance the best concepts through initial experiments via technical and financial support.

Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)

Amerika Birleşik Devletleri · US

Kimler başvurabilir Others (see text field entitled "Additional Information on Eligibility" for clarification)

This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

F26AS00069 Coastal Program FY26

Amerika Birleşik Devletleri · US

Kimler başvurabilir Native American tribal organizations (other than Federally recognized tribal governments) · Special district governments · Individuals · Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" · State governments · Independent school districts · Public and State controlled institutions of higher education · City or township governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Private institutions of higher education · Small businesses · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · Public housing authorities/Indian housing authorities

The U.S. Fish and Wildlife Service (Service) Coastal Program provides technical and financial assistance to partners to support projects that protect and restore fish and wildlife habitats on public and private lands in priority coastal ecosystems. This support is provided through cooperative agreements with conservation partners and landowners, including state and Tribal agencies. Coastal Program staff work with partners, stakeholders, and other Service programs in important areas for conservation. They implement regional strategic plans that identify priority species and habitats for conservation in these focus areas.Applicants seeking technical or financial assistance from the Coastal Program are required to contact a local Program office BEFORE developing or submitting an application. You can find this information in the current strategic plan at this link or by contacting your local Coastal Program office at https://www.fws.gov/program/coastal/contact-us.Projects are developed collaboratively by partners and Service field staff. All Coastal Program projects must align with the missions of the U.S. Department of the Interior, the U.S. Fish and Wildlife Service, and the Coastal Program. They are also based on sound biological principles and the best available science.

FY2026 Water Resources Research Act Non-Competitive Coordination

Amerika Birleşik Devletleri · US

Kimler başvurabilir Others (see text field entitled "Additional Information on Eligibility" for clarification)

Water Resource Research Act (WRRA) coordination award to support efforts toward water resources research.

DoW Breast Cancer, Transformative Breast Cancer Consortium Award

Amerika Birleşik Devletleri · US

Kimler başvurabilir Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges. Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Amerika Birleşik Devletleri · US

Kimler başvurabilir Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.

DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award

Amerika Birleşik Devletleri · US

Kimler başvurabilir Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Amerika Birleşik Devletleri · US

Kimler başvurabilir Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.